[A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine].

OBJECTIVE: For the first time, serum anti-HIV antibody negative conversion was being reported. METHODS: Eight confirmed HIV/AIDS patients (AC1, ARC 6, AIDS 1) were treated with TCM recipes (802, 806, 809, 810, Shengmaiyin, ZY-1), recheck the serum antibody and immunological function and intranuclear HIV-DNA was investigated with PCR amplifying assay and were long-term followed-up. RESULTS: After medication for 87-463 days, seronegative conversion occurred, PCR assay revealed that 5 cases were PCR(+), 2 of them(-), 1 turned seropositive again in the early stage. Observed continuously for 11-49 months, the "serum negative and intranuclear positive" state maintained. These patients belonged to immunosilent HIV-infection. The immunological function of all seronegative converted patients were good. CONCLUSIONS: AIDS is a reversible disease. Using medicinal herbs to enhance the immune function will facilitate the appearance of seronegative conversion, which has not been reported before. If it could be further confirmed, its mechanism elucidated, this may greatly strengthen the confidence of the patients.

[Screening of anti-simian immunodeficiency virus (SIV) drugs from Chinese medicinal herbs].

The inhibitory activities of more than 40 species of Chinese medicinal herbs or their single chemical components against simian immunodeficiency virus (SIV) have been studied. The study revealed that four species of the medicinal herbs and a single chemical component had more than 50% inhibition of SIV antigen expression and five other herbs' inhibitory rate of SIV antigen expression was between 30-50%. The results showed that Chinese medicinal herbs could inhibit the SIV activity.

[Immune function of cancer patients with spleen-deficiency syndrome].

According to this study, the immunological function was aberrant in cancer patients with Spleen-deficiency syndrome. The TII cell in normal persons (n = 26) was 30, 86 +/- 9.70% (means +/- S) and in these cases (n = 43) was 22.62 +/- 9.92%, P less than 0.002. The cytotoxicity of NK cell in patients (n = 59) was 17.65 +/- 10.58%, in normal controls (n = 43) was 25.51 +/- 14.10%. The combining ability of NK cell in patients (n = 48) was 39.11 +/- 19.43%, the normal persons (n = 41) was 55.88 +/- 17.94%. It showed that the immune function of the cancer patients with Spleen-deficiency syndrome were markedly lower than that of normal persons. The serum IgA in saliva of patients (n = 37) was 0.44 +/- 0.17 microgram/ml. It was much higher than that of normals' (n = 24, 0.30 +/- 0.06 microgram/ml), P less than 0.001. Some patients' NK cell function and the level of level of SIgA in saliva were recovered to normal after treatment of Shengxue Tang which could strengthen the Spleen and replenish the Kidney. These studies proved that the TCM played an important role for modulating immune function in treating cancer patients.

The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha mice.

This study examined the effect of mixed bacterial vaccine (MBV), a biological response modifier prepared from Streptococcus pyogenes and Serratia marcescens, on the immune system of mice and on the regression of a transplantable mouse tumor sarcoma 37. The study examined MBV's biological properties and analyzed its chemical composition. The chemical composition varied with the growth media. A typical centrifuged, dialyzed supernate of the serum-containing preparation was found to consist mainly of protein and minimal amounts of carbohydrate and endotoxin, while MBV made with synthetic medium contained similar amounts of all three. MBV was nontoxic for mice, which gained weight following the injection of 0.5-1.0 ml of MBV. MBV caused regression of 20-100% of well-established mouse tumors without appreciable toxicity. MBV also had a striking effect on the immune response of mice to sheep red blood cells. When administered simultaneously with antigen injection, MBV increased the number of antibody-secreting splenocytes measured by the plaque-forming assay threefold. Serum antibody levels also increased two- to threefold. MBV did not enhance the immune response to pneumococcal polysaccharide type III, a B-cell-dependent response. However, the in vivo administration of MBV increased the in vitro response to MBV and the B-cell mitogen lipopolysaccharide. MBV compares favorably with other biological response modifiers because of its enhancing effect on the immune response and its oncolytic properties at nontoxic levels.

Effect of the mixed bacterial vaccine on the immune response of patients with non-small cell lung cancer and refractory malignancies.

Since 1984, 13 patients were entered into our study and 12 patients have completed one or more cycles of treatment with mixed bacterial vaccine (MBV), a natural biologic response modifier derived from Streptococcus pyogenes and Serratia marcescens. Eight patients with refractory malignancy were treated with MBV only (0.1 ml intravenously [IV]) twice weekly for 3-16 weeks (colorectal cancer, pancreatic cancer, chronic lymphatic leukemia, hepatoma [two patients], sarcoma [three patients]). Four patients with advanced non-small cell lung cancer were treated with MBV in combination with low-dose cyclophosphamide, day 1; cisplatin, day 15; and MBV, 0.1 ml IV, days 5, 7, and 9. Two patients in this study received cyclophosphamide and cisplatin alone. The cycle was repeated every 28 days. Plasma interferon levels, interleukin-2 production by peripheral lymphocytes, and lymphocyte subpopulations were monitored. Interferon levels and interleukin-2 production showed increased or sustained values in general. In some patients, B-cells and helper T-cell populations increased, whereas T-suppressor cell numbers declined. With one exception, side effects were mild and consisted of fever greater than 37.8 degrees C (nine of 13), chills (11 of 13), increased respiratory rate (nine of 13), minor changes in blood pressure (seven of 13), and nausea (three of 13). One patient with non-small cell lung cancer had a partial response. Two patients with non-small cell lung cancer and one patient with refractory malignancy had stable disease and performance status at the end of 8 weeks of treatment; one patient with refractory malignancy was stable at the end of 4 weeks of treatment. In this pilot study, cancer patients treated with MBV showed objective evidence of immune stimulation with acceptable toxicity.